Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
US Stem Cell's gross profit for the
three
months ended in Dec. 2022 was $0.02 Mil. US Stem Cell's gross profit for the trailing twelve months (TTM) ended in Dec. 2022 was $0.06 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. US Stem Cell's gross profit for the
three
months ended in Dec. 2022 was $0.02 Mil. US Stem Cell's Revenue for the
three
months ended in Dec. 2022 was $0.02 Mil. Therefore, US Stem Cell's Gross Margin % for the quarter that ended in Dec. 2022 was 75.00%.
US Stem Cell had a gross margin of 75.00% for the quarter that ended in Dec. 2022 => Durable competitive advantage
US Stem Cell (OTCPK:USRM) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
US Stem Cell had a gross margin of 75.00% for the quarter that ended in Dec. 2022 => Durable competitive advantage
US Stem Cell Gross Profit Related Terms
US Stem Cell Gross Profit Historical Data
* Premium members only.
The historical data trend for US Stem Cell's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
USRM vs NOVNQ, RGRX, NMTRQ: Gross Profit Comparison
For the Biotechnology subindustry, US Stem Cell's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Gross Profit distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
US Stem Cell (USRM) has a Gross Profit of $0.06 Mil as of Dec. 2022. Gross Profit equals net sales less total cost of goods sold. View historical data on US Stem Cell and its competitors.
Is US Stem Cell's Gross Profit too high?
US Stem Cell's current Gross Profit is $0.06 Mil. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Gross Profit compare to NOVNQ and RGRX?
US Stem Cell's Gross Profit of $0.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on US Stem Cell and its competitors. US Stem Cell's current Gross Profit is $0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Gross Profit of $0.06 Mil. The current Gross Profit is $0.06 Mil. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For US Stem Cell (USRM), the current Gross Profit is $0.06 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score
Get the complete analysis for USRM
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USRM has been successfully added to your 
